New Caledonia vs Papua New Guinea: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
New Caledonia
2.3%
in 2024
Papua New Guinea
2.5%
in 2024
New Caledonia rank
12th
Papua New Guinea rank
11th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- New Caledonia
- Papua New Guinea
How they compare
Papua New Guinea currently reports 2.5% against 2.3% in New Caledonia, a difference of 0.2%.
That makes Papua New Guinea's figure about 1.1 times New Caledonia's.
Across all 10 years both countries report, Papua New Guinea has been ahead every year.
New Caledonia ranks 12th and Papua New Guinea ranks 11th of 246 countries.
Papua New Guinea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | New Caledonia | Papua New Guinea | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1.9% | 2.0% | 0.1% | Papua New Guinea |
| 2020s | 2.2% | 2.4% | 0.2% | Papua New Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, New Caledonia or Papua New Guinea?
- Papua New Guinea, at 2.5% against 2.3% in New Caledonia as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between New Caledonia and Papua New Guinea?
- 0.2%, with Papua New Guinea ahead.
- How many years of comparable data are there for New Caledonia and Papua New Guinea?
- 10 years are reported by both, from 2015 to 2024.
- How do New Caledonia and Papua New Guinea rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- New Caledonia ranks 12th and Papua New Guinea ranks 11th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.